The Cochrane Database of Systematic Reviews is a premier journal published by WILEY, focusing on the critical appraisal and synthesis of high-quality research in health care. With its dedication to evidence-based practice, this journal serves as a cornerstone for researchers, healthcare professionals, and students alike, offering pivotal insights through rigorous systematic reviews. Although it is not an open-access publication, its influence in guiding clinical decision-making and policy formulation is profound, underscored by its contributions to the advancement of healthcare knowledge. Based in the United States at 111 River St, Hoboken, NJ, the Cochrane Database has established itself as essential reading for those seeking to stay at the forefront of systematic reviews and meta-analyses in the medical field, ensuring that users are well-equipped with the evidence necessary for informed practice.

Clinical Obesity, published by WILEY, is a leading journal in the field of Endocrinology, Diabetes, and Metabolism that strives to advance the understanding of obesity-related health issues. With an ISSN of 1758-8103 and an E-ISSN of 1758-8111, this journal provides a platform for cutting-edge research and findings pertaining to the epidemiology, pathophysiology, prevention, and treatment of obesity. Recognized with a Q2 ranking in both Endocrinology, Diabetes and Metabolism and Medicine (miscellaneous) categories, and boasting a Scopus rank of #90 out of 244, Clinical Obesity encompasses innovative studies that influence clinical practice and public health policies. While this journal operates under a subscription model, its discipline-specific contributions are invaluable for researchers, healthcare professionals, and students keen on addressing the complexities of obesity in a comprehensive manner.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

EPILEPSY RESEARCH is a distinguished journal published by Elsevier, focusing on the dynamic field of neurology with a specific emphasis on epilepsy and related neurological disorders. Since its inception in 1987, the journal has become a vital platform for disseminating cutting-edge research, contributing significantly to the understanding of epileptic conditions and their clinical implications. With an impactful presence in the academic community, EPILEPSY RESEARCH currently holds a 2023 Q2 ranking in both the Neurology and Clinical Neurology categories, reflecting its commitment to high-quality, peer-reviewed content. The journal is indexed in SCOPUS, Ranking #173/400 in Clinical Neurology and #91/192 in Neuroscience, ensuring widespread visibility and academic engagement. Although not an open access publication, it provides critical insights, findings, and reviews that are essential for researchers, clinicians, and students alike, fostering advancements in epilepsy research and treatment. For any inquiries, the journal is based at Radarweg 29, 1043 NX Amsterdam, Netherlands.

Archives of Epilepsy is a pioneering academic journal dedicated to advancing the field of epilepsy research and clinical practice. Published by GALENOS PUBL HOUSE in Turkey, this Open Access journal has embraced the principle of unrestricted access since its inception in 2012, allowing researchers, healthcare professionals, and students from around the world to engage with cutting-edge findings in neuropathology. With a focus on clinical and neuroscience aspects of neurology, the journal occupies a significant position in the academic landscape, currently ranked in the Q4 quartile in both Neurology and Clinical Neurology categories as of 2023. Though it faces challenges in its Scopus rankings with a current percentile of 2nd in Medicine - Neurology (Clinical) and 1st in Neuroscience - Neurology, it offers a valuable platform for emerging studies. The journal's commitment to fostering a comprehensive understanding of epilepsy is crucial, as it facilitates broader discourse on effective treatments and patient care strategies. We invite researchers and practitioners to explore the impactful articles published in the Archives of Epilepsy and contribute to an evolving dialogue that strives to improve outcomes for individuals affected by epilepsy.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

SEIZURE - EUROPEAN JOURNAL OF EPILEPSY is a leading journal published by W B SAUNDERS CO LTD, specializing in the field of epilepsy and seizure disorders. Since its inception in 1992, this journal has committed itself to advancing research and understanding in neurology, achieving a respectable 2023 impact factor reflected by its Q2 rankings in Medicine (miscellaneous), Neurology, and Clinical Neurology categories. With an impressive Scopus ranking that places it in the top 35% of journals in Neuroscience and Neurology, SEIZURE is dedicated to promoting high-quality research and clinical studies that offer insights into epilepsy management and treatment. Although not an open-access journal, it maintains a diverse array of original articles, reviews, and case studies catering to academicians, medical professionals, and students looking to expand their knowledge on epilepsy. This journal is pivotal for those seeking to stay abreast of the latest trends, therapies, and findings in the neuroclinical landscape.